Triangle Pharmaceuticals Incorporated

Triangle Pharmaceuticals develop new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus ("HBV"). Triangle Pharmaceuticals have an existing portfolio of six licensed drug candidates and one drug candidate for which they have an option to acquire a license. Five of these drug candidates are currently under active development. Triangle Pharmaceuticals goal is to capitalize on our management team's expertise, as well as on advances in virology and immunology, to identify, develop and commercialize new drug candidates that can be used alone or in combination (coactively) to treat serious diseases.

Contact Details: 4 University Place4611 University Drive Durham NC 27707 United States of America Tel: 919 493 5980 Fax: 919 493 5925 Email: WWW: www.tripharm.com/

Loading...

Recent Publications by Triangle Pharmaceuticals Incorporated:
Synthesis of (-)-DAPD. A new synthesis of (-)-DAPD, suitable for large scale development, is...	6th May, 2005	Division of Organic Chemistry, Triangle Pharmaceuticals Inc., Durham,	Nucleosides Nucleotides Nucleic Acids. 2004;23(12):1875-87.
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Emtricitabine (FTC; Emtriva), a potent deoxycytidine nucleoside reverse...	21st February, 2004	Triangle Pharmaceuticals, Inc., Gilead Sciences, Inc., Durham, North	Antimicrob Agents Chemother. 2004 Jan;48(1):183-91.
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. We conducted a randomized, open-label, 10-day study that compared the...	7th January, 2004	Triangle Pharmaceuticals, Durham, North Carolina 27717, USA.	J Infect Dis. 2003 Dec 1;188(11):1652-8. Epub 2003 Oct 31. DOI Direct Link
Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in...	8th July, 2003	Triangle Pharmaceuticals, Inc., a subsidiary of Gilead Sciences, Durham,	J Biol Chem. 2003 May 23;278(21):18971-9. Epub 2003 Mar 21. DOI Direct Link
Reproductive toxicology profile of emtricitabine in mice and rabbits. Reproductive and developmental toxicology studies were conducted with...	25th June, 2003	Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530,	Reprod Toxicol. 2003 Jan-Feb;17(1):95-108.
→View more Triangle Pharmaceuticals Incorporated research publications.

BioNews Results for Triangle Pharmaceuticals Incorporated:
Senior Director of Biotechnology at Catalent To Present Course on Bioassays	Express Press Release:  Nov 13 2009 3:30AM Matching: triangle pharmaceuticals
Executive Appointments at Patheon	Contract Pharma:  Nov 11 2009 12:25AM Matching: triangle pharmaceuticals
Patheon, Inc. Adds Two Key Industry Leaders To Its Pharmaceutical Development Services Business	Bioresearch Online:  Nov 10 2009 5:49AM Matching: triangle pharmaceuticals
Patheon, Inc. adds two key industry leaders to its pharmaceutical development services business	Pharma Live:  Nov 9 2009 8:20PM Matching: triangle pharmaceuticals
Pfizer shuttering 6 of its 20 research-and-development facilities	MarketWatch:  Nov 9 2009 5:36PM Matching: triangle pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Triangle Pharmaceuticals Incorporated news.

Triangle Pharmaceuticals Incorporated Clinical Trials:
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Triangle Pharmaceuticals Incorporated Patents:
US Patent No.	Title
6870048	Process for the preparation of 2'-halo-.beta.-L-arabinofuranosyl nucleosides
5660858	Cyclosporin emulsions
5785975	Adjuvant compositions and vaccine formulations comprising same
5885956	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
5922355	Composition and method of preparing microparticles of water-insoluble substances
→View more Triangle Pharmaceuticals Incorporated patents.

Triangle Pharmaceuticals Incorporated (VIRS) Financial information Links from Barchart
VIRS Quote from from Barchart.com
VIRS Chart from from Barchart.com
VIRS Profile from from Barchart.com
VIRS Opinion from from Barchart.com
→View more Triangle Pharmaceuticals Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 760 times since April 2007, the link to the organisation's website has been followed 118 times

Recent Search Terms used to find this page: triangle pharmaceuticals | biomarck pharmaceuticals | triangle pharmaceuticals | Triangle Pharma | Triangle Pharmaceuticals contact | triangle pharmaceuticals inc. | Triangle Ph | triangle pharma | Triangle Pharmaceuticals | Triangle Pha | .

Search for more companies in Durham

Search for more companies in NC

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Triangle Pharmaceuticals Incorporated